13F Holdings
中文EN

HCWB HCW Biologics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1828673 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,487.6%
TTM net income YoY64.7%
TTM EPS YoY162.3%
Revenue 3-yr CAGR32.8%
Net income 3-yr CAGR—

Margins

Gross margin96.6%
Operating margin-104.2%
Net margin-63.4%
FCF margin—
EBITDA margin-96.1%

Returns

ROE-180.3%
ROA-16.8%
ROIC (approx.)-116.5%
Asset turnover0.26x

Leverage & solvency

Liabilities / assets72.8%
Debt / equity0.00x
Current ratio0.07x
Interest coverage-12.39x

Cash quality & payout

Operating cash flow / net income2.71x
Accruals ratio28.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$54,232$2.57M$2.84M$6.72M$0
Cost of revenue$43,386$1.61M$2.28M$4.14M$0
Gross profit$10,846$959,403$560,360$2.59M$0
R&D expense$5.44M$6.39M$7.68M$9.34M$8.17M
SG&A expense$7.70M$6.82M$6.78M$8.33M$5.19M
Operating income-$13.16M-$29.46M-$25.72M-$15.08M-$13.37M
Interest expense$845,051$654,284$283,042$126,660$0
Pretax income-$7.96M-$30.02M-$24.99M-$14.90M-$12.86M
Income tax$0$0$0$0$0
Net income-$7.96M-$30.02M-$24.99M-$14.90M-$12.86M
EBITDA-$12.12M-$28.27M-$24.58M-$14.36M-$12.82M
EPS (basic)-10.63-30.96-0.70-0.42-0.69
EPS (diluted)-10.63-30.96-0.70-0.42-0.69
Weighted avg. shares (diluted)2.10M969,82535.93M35.82M18.77M
Balance sheet
Cash & equivalents$1.95M$4.67M$3.60M$22.33M$11.73M
Short-term investments$0$0$0$9.74M$24.98M
Receivables$32,175$582,201$1.54M$417,695$133,000
Current assets$2.28M$5.70M$6.40M$34.07M$40.48M
PP&E, net$20.88M$22.91M$20.45M$10.80M$1.12M
Total assets$24.52M$30.24M$28.51M$46.81M$53.51M
Current liabilities$21.06M$29.63M$8.75M$2.96M$2.32M
Short-term debt$6.81M$6.31M$0$38.27M—
Long-term debt$0$7.38M$6.30M$6.41M$0
Total debt$6.81M$13.69M$6.30M$44.68M$0
Total liabilities$21.76M$37.01M$15.05M$9.38M$2.32M
Shareholders' equity$2.76M-$6.77M$13.46M$37.43M$51.19M
Net debt$4.86M$9.02M$2.71M$22.36M-$11.73M
Cash flow statement
Operating cash flow-$13.39M-$14.23M-$22.51M-$10.39M-$10.98M
Capital expenditure$0$261,617$6.20M$10.28M$47,263
Free cash flow-$13.39M-$14.49M-$28.72M-$20.66M-$11.02M
Investing cash flow$0-$261,617$3.80M$14.71M-$35.02M
Financing cash flow$10.67M$15.57M-$14,534$6.27M$49.27M
Depreciation & amortization$1.04M$1.18M$1.14M$717,854$543,598
Stock-based compensation$768,623$1.01M$1.00M$1.12M$360,975

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.